297 related articles for article (PubMed ID: 8706358)
1. Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado CE; Flombaum CD
Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
[TBL] [Abstract][Full Text] [Related]
2. Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment.
Yap AS; Hockings GI; Fleming SJ; Khafagi FA
Clin Nephrol; 1990 Nov; 34(5):225-9. PubMed ID: 2268980
[TBL] [Abstract][Full Text] [Related]
3. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
Sekine M; Takami H
Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
[TBL] [Abstract][Full Text] [Related]
4. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
[TBL] [Abstract][Full Text] [Related]
5. Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.
Vega EM; Mautalen CA
Medicina (B Aires); 1991; 51(2):106-10. PubMed ID: 1820495
[TBL] [Abstract][Full Text] [Related]
6. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
7. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
[TBL] [Abstract][Full Text] [Related]
8. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
9. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
[TBL] [Abstract][Full Text] [Related]
10. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
11. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
12. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
Banerjee D; Asif A; Striker L; Preston RA; Bourgoignie JJ; Roth D
Am J Kidney Dis; 2003 May; 41(5):E18. PubMed ID: 12778436
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
14. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate.
Cagle AP; Waguespack SG; Buckingham BA; Shankar RR; Dimeglio LA
Pediatrics; 2004 Oct; 114(4):1091-5. PubMed ID: 15466114
[TBL] [Abstract][Full Text] [Related]
15. [How to treat tumor-induced hypercalcemia].
Body JJ
Rev Prat; 2003 Dec; 53(19):2128-35. PubMed ID: 15008469
[TBL] [Abstract][Full Text] [Related]
16. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
19. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Yates AJ; Murray RM; Jerums GJ; Martin TJ
Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis.
Alos N; Eugène D; Fillion M; Powell J; Kokta V; Chabot G
Horm Res; 2006; 65(6):289-94. PubMed ID: 16612105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
